29 October 2021 -Aker BioMarine ASA ("Aker BioMarine " or "the company") reports revenues ofUSD 62.0 million and Adjusted EBITDA ofUSD 14.6 million in the third quarter 2021. "In the quarter, we delivered revenues and earnings as expected and we reiterate our full-year guidance. Sales of Qrill and our private label brand in the US were at a good level, while sales of the krill oil brand Superba was low also in this quarter. Powerful growth initiatives are now implemented, and we target higher sales already in the next quarter. We had a positive end to the 2021 krill harvesting season inAntarctica and we look forward to the new one that starts late November" saidMatts Johansen , CEO ofAker BioMarine . Third quarter highlights: - Revenues ofUSD 62.0 million (compared toUSD 70.2 million in the same period last year) - Adjusted EBITDA ofUSD 14.6 million (USD 26.8 million ), with 24% (38%) Adjusted EBITDA margin in the quarter. Adj. EBITDA included a net gain ofUSD 2.45 million from sale of fuel option contracts - Sales in Ingredients declined 21% in the quarter versus same period last year. Qrill sales were down 3%, while Superba sales were 42% below same period last year. A growth plan for Superba is being implemented with several near-term initiatives, including new sales strategies and organization, new claims and new product offerings - The market reach for Kori, our retail brand in the US, further increased with two large retailers moving to full distribution in stores in the first quarter 2022 - Harvesting volumes of 7,195 MT in the quarter compared to 8,727 MT in the same period last year - A new record-quarter at theHouston facility with production increasing 24% from same period last year with all-time-low unit cost - Refinancing structure agreed with a three-bank syndicate. Improved terms and conditions, as well as increased flexibility related to covenants and dividends Outlook:Aker BioMarine reiterates the guiding for 2021 with expected sales at somewhat below last year's revenue and with an expected adjusted EBITDA margin of 15-17%. The company still expects harvesting volume for the year to be in the range of 40,000 - 45,000 MT, depending on harvesting conditions in the fourth quarter.Aker BioMarine will host a Capital Markets Update on1 December 2021 , where a more detailed presentation of the company and its efforts to improve earnings and growth will be given. It will be a fully digital event. At09:00 CEST today, the management will host a Q3 conference call. Following a brief presentation, there will be a Q&A session, where written questions can be submitted over a Teams Live Event. The webcasted presentation will be in English. To join, please use the following link: https://teams.microsoft.com/l/meetup-join/19%3ameeting_MDEyYzkyNjgtYjlmYi00MTQ2L TljZTAtYmZlOTg5MWVhMjYy%40thread.v2/0?context=%7b%22Tid%22%3a%22f3733015-082c-4a a6-8823-36db9bfdc6ba%22%2c%22Oid%22%3a%2276bab8a9-cee6-4245-ade2-eb08f5723da4%22 %2c%22IsBroadcastMeeting%22%3atrue%7d&btype=a&role=a A link to the presentation is also available at www.akerbiomarine.com/investor. A replay of the presentation and Q&A session, in addition to the quarterly report and presentation material, will be made available soon after the presentation at the same web address. For further information, please contactCarl Christian Bachke , Investor Relations Mobile: +47 909 808 48 Email: carl.bachke@akerbiomarine.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. AboutAker BioMarine Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters ofAntarctica .Aker BioMarine is listed onOslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.
Click here for more information
© Oslo Bors ASA, source